Clinical data on Bundibugyo virus (BDBV) infection are limited and no virus-specific licensed treatment exists. The article describes a single-case clinical report of a previously healthy 39-year-old healthcare worker who contracted BDBV while working in Ituri Province, Democratic Republic of the Congo (DRC). The patient was medically evacuated to Germany for specialized care. This brief communication shares clinical, virologic and immunologic observations during combined antiviral therapy and supportive care.
Under an FDA Emergency Investigational New Drug (eIND) authorization, the patient received MBP134, an investigational combination of two monoclonal antibodies, in addition to remdesivir and supportive care. MBP134 is described as a two-antibody monoclonal combination; details such as dosing schedules, administration timing relative to symptom onset, and exact remdesivir regimen were not reported in the source summary.
Supportive care measures are mentioned but not enumerated in the provided text. The report focuses on clinical outcomes, virologic kinetics in multiple specimen types and the development of endogenous antibody responses in the setting of combined antiviral therapy.
Quantitative detection of viral RNA demonstrated that concentrations were highest in oropharyngeal swabs and plasma early in the clinical course. Viral RNA became undetectable in blood, throat swabs, urine and stool by day 13 after symptom onset. Semen samples were reported as negative by day 25 after symptom onset. These results indicate clearance of detectable viral RNA from multiple body compartments within the time frames described.
The source notes specimen-specific kinetics but does not provide numerical viral-load values, cycle-thresholds, or detailed temporal sampling beyond the timepoints summarized above. No additional virologic parameters (for example culture results or infectious virus assays) were reported in the provided abstract text.
Serologic testing demonstrated that the patient’s serum had neutralizing activity against the circulating BDBV outbreak strain and against other orthoebolaviruses. Importantly, investigators detected BDBV-induced antibody responses that could not be attributed to MBP134 administration or to prior vaccination, providing evidence that the patient mounted an endogenous humoral immune response while receiving combined antiviral treatment.
The source indicates both treatment-related and host-derived antibody signals were assessed; however, the summary does not specify the assays, neutralization titers, kinetics of seroconversion, or the timing of antibody measurements in relation to dosing. Those assay-level details were not reported in the provided text.
The patient recovered clinically and was discharged from care on day 22 after symptom onset. The case report links clinical recovery with virologic clearance in multiple specimen types and the detection of endogenous neutralizing antibodies, suggesting that combined use of MBP134 and remdesivir in this single patient was associated with a favorable outcome.
No detailed clinical severity scores, laboratory trends, imaging findings or specific adverse events related to MBP134 or remdesivir are described in the source abstract. The limited clinical descriptors in the summary preclude definitive attribution of recovery to any single component of the combined therapy.
This brief communication reports detailed observations from a single case and explicitly calls for larger clinical studies to assess the efficacy and clinical utility of monoclonal antibody combinations such as MBP134 and antiviral agents such as remdesivir for BDBV infection. Key limitations inherent to the report include the single-patient design and the absence, in the provided summary, of full dosing details, comprehensive laboratory data, and controlled comparisons.
The case provides useful clinical and biological insights — notably specimen-specific virologic clearance timelines and evidence of an endogenous neutralizing antibody response despite administration of exogenous monoclonal antibodies — but cannot establish causality or generalizable efficacy. The authors emphasize the need for larger, systematic clinical evaluations to determine safety, optimal timing, dosing and therapeutic benefit for BDBV-specific treatments.
In summary, this report documents a medically evacuated 39-year-old with BDBV infection who received investigational MBP134 monoclonal antibodies and remdesivir, cleared detectable viral RNA from multiple specimen types by day 13 (and from semen by day 25), developed endogenous neutralizing antibody responses, and recovered clinically with discharge on day 22 after symptom onset. The report contributes case-level virologic and immunologic observations while underscoring the requirement for larger clinical studies to assess treatment efficacy and clinical utility.
Note on source limitations: the supplied article summary did not report detailed dosing regimens, timing of each therapeutic administration relative to symptom onset beyond the information above, specific laboratory values, or detailed adverse event data; those details are therefore not included here.